Biogen shares plunge as Alzheimer’s drug trial disappoints

Biogen shares plunge as Alzheimer’s drug trial disappoints

Biogen and partner Eisai are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab. Shares of Biogen slipped significantly following the announcement and the company lost more than $18 billion of its value on Thursday. Without potential future revenue from Alzheimer’s, Biogen has poor growth prospects.

KCooper
KCooper
Miles O'Brien
Miles O'Brien 1 year

Did they abandon it or forget that it was there?

Top in Business
Get the App